![\"\"](\"https:\/\/mft.nhs.uk\/app\/uploads\/sites\/16\/2025\/02\/SCD_Gene_Therapy_Circle.jpg\")
<\/p>\n<\/p>\n
Revolutionary Gene Therapy Offers Hope for Sickle Cell Cure for NHS Patients<\/u><\/strong><\/p>\n New Therapy Details<\/strong><\/p>\n In a groundbreaking development, NHS England has approved a revolutionary gene-editing therapy offering a potential cure for sickle cell disease.<\/p>\n This one-time treatment called exagamglogene autotemcel, or simply exa-cel, targets the root cause of sickle cell by editing a gene in bone marrow stem cells. Clinical trials have shown a “functional cure” in nearly all participants, eliminating painful sickle cell crises and hospitalisations. NHS Chief Executive Amanda Pritchard hailed this as a “leap in the right direction,” offering patients a chance at a disease-free life.<\/p>\n When and where will this treatment be available, and who is eligible to receive it?<\/strong><\/p>\n The National Institute for Health and Care Excellence (NICE) has approved exa-cel gene therapy for use on the NHS in England from Friday 31st<\/sup> January 2025. It is for eligible children and adults with severe sickle cell disease. Namely patients who are aged 12 years or older, have recurrent crises & lack a stem cell donor.<\/p>\n Haematology clinical staff will have the full details of the treatment, and any restrictions, so you should ask them for more information.<\/p>\n The treatment will be available at specialist NHS centres in London, Manchester, and Birmingham. Around 50 patients a year are expected to benefit. Experts and patient advocates are celebrating this milestone, emphasising its potential to transform lives and address health inequalities. The therapy’s availability marks a significant advancement in the treatment of sickle cell disease and offers hope for a brighter future for those affected.<\/p>\n More Information<\/strong><\/p>\n NHS England website:<\/p>\n